Ask whether the panel tests APP, PSEN1, and PSEN2, what it can and cannot rule out, who pays, and what a positive result means for insurance and relatives. These three genes drive early-onset familial Alzheimer's disease (EOFAD), an inherited form that causes symptoms before age 65, and a mutation turns up in roughly 40-80% of families with a clear pattern of early-onset dementia passed down through generations, according to Blue Cross NC's medical policy. A memory clinic visit moves faster when you arrive with these questions already answered for yourself: your family's history, your reason for testing, and what you'd do with each possible result. The sections below walk through what to ask, in the order a clinic typically raises them.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which genes does the panel cover, and does your family history qualify?
- Is there a current clinical guideline the clinic is following, or is this judgment call?
- Will APOE testing come up, and is that a different conversation?
- What does a positive result mean for insurance, and for your relatives?
- Who pays, and what should you ask about cost before testing?
- Frequently Asked Questions
Which genes does the panel cover, and does your family history qualify?
Confirm the panel targets APP, PSEN1, and PSEN2, the three genes linked to early-onset familial Alzheimer's. A clinic orders this panel for people with a known mutation already found in a first-degree relative, a strong multi-generation pattern of early-onset dementia, or early-onset symptoms in someone whose family history is unknown, such as an adopted patient, under Blue Cross NC's coverage criteria. Ask the clinic to map your own family tree against those criteria before ordering anything.
A pattern that skips generations, or symptoms that started after 65, points away from EOFAD and toward other causes that this panel will not identify. Ask, too, whether a negative result is useful. A negative result in a family with a documented mutation is far more informative than a negative result in a family where no mutation has ever been found, since the panel can only rule out what it has already confirmed exists elsewhere in the family.
Is there a current clinical guideline the clinic is following, or is this judgment call?
Ask directly whether the clinic is following a graded practice guideline or using its own clinical judgment. The joint 2011 statement from the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) was downgraded to a non-evidence-graded Practice Resource — first by NSGC in 2016, then confirmed by ACMG in 2018 — meaning there is no current graded professional guideline governing this testing, per the ACMG addendum. That gap matters practically: it means two clinics can reasonably reach different conclusions about whether to order the panel for your situation.
Ask what the clinic's own threshold is and why, rather than assuming a single national standard applies. Also ask whether pre-test and post-test genetic counseling is built into the visit or scheduled separately. Insurer policy requires both around diagnostic APP/PSEN1/PSEN2 testing, and a clinic that skips this step is skipping a step insurers themselves expect, per Blue Cross NC.
Will APOE testing come up, and is that a different conversation?
Ask whether the clinic plans to discuss APOE testing separately from the EOFAD panel, since the two serve different purposes. APOE is a risk gene, not a causative one: carrying the ε4 variant raises the odds of developing Alzheimer's but does not guarantee it, and FEP Blue's own 2026 policy calls APOE testing for general risk assessment investigational outside of guiding anti-amyloid drug therapy, per the FEP Blue medical policy. If anti-amyloid treatment such as lecanemab or donanemab is on the table, ask whether APOE testing is being recommended for that specific reason.
The FDA label for lecanemab places APOE ε4 status inside its boxed warning on ARIA (amyloid-related imaging abnormalities) and recommends testing before treatment so prescribers can gauge risk, including the roughly 15% of Alzheimer's patients who carry two copies of ε4, per the FDA label. Donanemab's label carries the same boxed warning and the same testing recommendation, leaving the final treatment decision to clinical judgment rather than mandating the test, according to Alzforum's reporting on the FDA labeling. Ask what happens if you decline APOE testing. Both drug labels describe testing as recommended, not mandatory, so a patient who opts out can still be considered for treatment without a determined homozygote risk level.
What does a positive result mean for insurance, and for your relatives?
Ask the clinic to spell out exactly which insurance protections apply and which don't. The Genetic Information Nondiscrimination Act bars health insurers and employers from using APOE or PSEN/APP results against you, but those protections stop there — life, disability, and long-term-care insurers can still request results and factor them into coverage or pricing, according to the NHGRI fact sheet.
Some states add further protections, so ask whether yours is one of them. Ask what a positive result would mean for siblings, children, or other relatives who haven't been tested. Because EOFAD mutations are inherited in an autosomal-dominant pattern, a confirmed mutation in you directly raises the question of testing for first-degree relatives, which is part of why pre-test counseling matters.
- Ask whether the clinic recommends against predictive testing in people without symptoms, consistent with the original 1996 NIA/Alzheimer's Association guidance against using APOE genotyping to predict future disease in asymptomatic people, per the NIA/Alzheimer's Association summary.
- Ask who else in the family should know results before they're shared.
- Ask whether the clinic can connect you with a genetic counselor independent of the ordering physician.
Who pays, and what should you ask about cost before testing?
Ask about out-of-pocket cost before any panel is ordered, especially for APOE. Medicare contractors generally do not cover APOE genotyping, and there is no national coverage determination for it, so a memory clinic patient on Medicare should expect to pay for that test directly unless a specific treatment-related exception applies, according to reporting referencing CMS coverage policy. Ask separately about the EOFAD panel's cost and coverage, since insurer criteria for APP/PSEN1/PSEN2 testing differ from APOE's.
If you meet the criteria for a known familial mutation, strong family history, or unexplained early-onset symptoms, ask the clinic to document that reasoning in the order, since that documentation is often what coverage review examines first, per Blue Cross NC. A 2024 study in Nature Medicine found that nearly all people with two copies of the APOE ε4 allele showed biological markers of Alzheimer's pathology years before any diagnosis, a finding that has prompted some researchers to argue APOE4 homozygosity should be treated as a genetic form of the disease rather than a simple risk factor — though not every homozygote in the study went on to develop symptoms, according to a WebMD summary of the research. Ask the clinic how that evidence, if it applies to your results, would change the plan going forward.
Frequently Asked Questions
Does the EOFAD panel test the same genes as APOE testing?
No. The EOFAD panel covers APP, PSEN1, and PSEN2, which can directly cause early-onset Alzheimer's, while APOE is a separate risk gene that raises odds without causing disease on its own.
Can a clinic require APOE testing before prescribing lecanemab or donanemab?
Both drug labels recommend APOE testing before treatment to assess ARIA risk, but testing is described as recommended rather than mandatory in either label.
Will a positive EOFAD result affect my life insurance?
It can. Federal genetic nondiscrimination protections cover health insurance and employment but not life, disability, or long-term-care insurance, which can request and use the results.
